Levetiracetam 1a Farma (Levetiracetam)

Levetiracetam exerts its effect by binding to the synaptic vesicle protein SV2A in the central nervous system. This binding modulates neurotransmitter release, stabilizes neuronal firing, and diminishes excessive neuronal excitability that can trigger seizure activity.

The appropriate dose of levetiracetam is determined by the prescribing physician based on individual factors such as the type of seizure, patient age, renal function, and clinical response. Dosage adjustments are made to achieve optimal seizure control while minimizing side effects.

Safety data for levetiracetam in pregnancy are limited, and it is classified as having an unknown pregnancy risk. Use during pregnancy should only occur when the potential benefit justifies any possible risk to the fetus. Breastfeeding decisions should be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India serves hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. The sales team then provides pricing, availability, shipping details (including any required cold‑chain handling), and assists with import documentation.

Compared with older antiepileptics such as carbamazepine or valproate, levetiracetam offers a favorable pharmacokinetic profile with minimal protein binding and few drug‑enzyme interactions. It is generally well tolerated, but clinicians may choose it over alternatives when rapid titration, fewer metabolic concerns, or a specific seizure type (e.g., myoclonic seizures) is desired.

Levetiracetam 1a Farma should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in their original container, protect them from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

The medication is taken orally. Tablets are swallowed whole with a glass of water and can be taken with or without food. Patients should follow the dosing schedule prescribed by their healthcare provider and avoid crushing or chewing the tablets unless specifically instructed.

Serious adverse events, although uncommon, include severe skin reactions such as Stevens‑Johnson syndrome, suicidal thoughts or behaviors, significant mood changes including depression, and hematologic abnormalities like leukopenia or thrombocytopenia. Prompt medical attention is required if any of these symptoms arise.

Levetiracetam is contraindicated in individuals with a known hypersensitivity to the drug or any of its components. Caution is advised for patients with severe renal impairment, uncontrolled psychiatric conditions, or those who have experienced serious adverse reactions to levetiracetam in the past.